Table 3.
Prevalence of features in eyes treated with selective intra-arterial chemotherapy on pre- and posttreatment MRI scans.
| Scanning Time | Pretreatment MRI | Posttreatment MRI |
|---|---|---|
| Feature | n of events/n of eyes, % (95% CI) | n of events/n of eyes, % (95% CI) |
| Ocular | ||
| Retinal detachment | 87/184, 47 (38–58) | 82/234, 35 (29–42) |
| Subretinal hemorrhage | 43/182, 24 (17–31) | 37/234, 16 (11–21) |
| Vitreous hemorrhage | 3/183, 2 (0–5) | 5/234, 2 (1–4) |
| Enhancement of the anterior eye segment | n/a | 55/231, 24 (18–30) |
| Choroidal infarction | n/a | 24/233, 10 (7–15) |
| Choroidal thickening | n/a | 62/234, 27 (21–33) |
| Orbital (Preseptal space) | n/a | |
| Palpebral inflammation (cellulitis) | n/a | 29/231, 13 (9–18) |
| Orbital (Postseptal space) | n/a | |
| Extraocular muscle fibrosis | n/a | 1/234, 0 (0–2) |
| Extraocular muscle inflammation (myositis) | n/a | 68/233, 29 (23–35) |
| Orbital fat enhancement (cellulitis) | n/a | 41/232, 18 (13–24) |
| Orbital fat necrosis | n/a | 2/232, 1 (0–7) |
| Optic nerve enhancement | n/a | 15/233, 6 (4–10) |
| Perineural optic nerve fibrosis | n/a | 1/226, 0 (0–2) |
| Intracranial | ||
| Cerebral infarction | n/a | 3/234, 1 (0–4) |
Note.—Data presented as number of events versus number of eyes and percentages with 95% confidence interval in parentheses. n/a = not applicable.